N Acetyl Selank Research
Share
N-acetyl Selank is not a recognized term in the medical literature. However, Selank itself is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) that has been studied for its potential anxiolytic and nootropic effects.
Selank has been shown to exhibit prolonged anti-anxiety effects, which are thought to be mediated through its interaction with the GABAergic system. Specifically, Selank acts as a positive allosteric modulator of GABA receptors, which enhances the binding of GABA to its receptors and thereby exerts an anxiolytic effect.[1] This mechanism is similar to that of classical benzodiazepines, although Selank does not appear to induce the same level of dependence or memory impairment commonly associated with benzodiazepine use.
In addition to its effects on GABA receptors, Selank has been found to influence the expression of genes involved in neurotransmission. Studies have demonstrated that Selank administration can alter the expression of numerous genes related to the GABAergic system, suggesting a complex mechanism of action that extends beyond simple receptor modulation.[2] These changes in gene expression may contribute to the peptide's overall anxiolytic and cognitive-enhancing effects.
Furthermore, Selank has been shown to interact with other pharmacological agents. For instance, it can modulate the effects of diazepam and olanzapine, indicating that its binding sites may partially overlap with those of these drugs.[1] This interaction suggests potential for Selank to be used in combination with other anxiolytics or antipsychotics, although further research is needed to fully understand these interactions and their clinical implications.
Overall, Selank represents a promising peptide-based therapeutic for anxiety and cognitive disorders, with a unique mechanism of action that involves modulation of the GABAergic system and gene expression. Further clinical studies are warranted to fully elucidate its therapeutic potential and safety profile.
1. Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Protein and Peptide Letters. 2018;25(10):914-923. doi:10.2174/0929866525666180925144642.
2. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Volkova A, Shadrina M, Kolomin T, et al. Frontiers in Pharmacology. 2016;7:31. doi:10.3389/fphar.2016.00031.